ADMA Biologics Q2 GAAP net income rises 11% to $37.8 million; revenue increases 2% to $124.4 million - ADMA News | RalliesADMA Biologics Q2 GAAP net income rises 11% to $37.8 million; revenue increases 2% to $124.4 million
A
ADMA• Q2 results and guidance
- ADMA Biologics posted 2Q 2026 GAAP net income of USD 37.8 million, up 11% year-over-year; GAAP basic EPS rose 17% to USD 0.17.
- Revenue climbed 2% year-over-year to USD 124.4 million, driven by ASCENIV revenue of USD 102.9 million, up 24%.
- BIVIGAM revenue fell 49% year-over-year to USD 19.4 million, though utilization stabilized with sequential improvement in demand and revenue.
- Gross margin widened 14 percentage points to 69% on a mix shift toward ASCENIV and the yield-enhanced manufacturing process approved in 2025.
- Reiterated FY2026 guidance for revenue of USD 530 million to USD 560 million, adjusted EBITDA of USD 265 million to USD 300 million.
NTZ
•
